Office Phone:
Harvard Medical School

Current Research Interests

Dr. Basch is a practicing medical oncologist and health services researcher whose work focuses on the use of patient-reported measures to assess drug toxicity and symptom endpoints in clinical research, routine care, and quality assessment.  His group established that the current approach to adverse event reporting in oncology misses essential information about the patient experience, which can be captured via direct patient reporting.  His work has been published in the New England Journal of Medicine, JAMA, the Lancet, Lancet Oncology, Journal of Clinical Oncology, Journal of the National Cancer Institute, and Journal of the American Medical Informatics Association.  He leads the National Cancer Institute’s initiative to create a patient version of the standard lexicon for adverse event reporting in oncology trials, the Common Terminology Criteria for Adverse Events (PRO-CTCAE).  He is a member of the Board of Scientific Advisors of the National Cancer Institute, a member of the Methodology Committee of the Patient-Centered Outcomes Research Institute (PCORI), Co-Chair of the Health Outcomes Committee for the Alliance cooperative group, Board Member of the International Society for Quality of Life Research (ISOQOL), and has led multiple guideline panels for the American Society of Clinical Oncology (ASCO). His research is funded by grants and contracts from the NCI, Department of Defense, ASCO, and multiple foundations.  He is currently a faculty member at Memorial Sloan Kettering Cancer Center with ongoing research based at MSKCC, but spends most of his time at the University of North Carolina at Chapel Hill, where he is Director of the Cancer Outcomes Research Program.  Dr. Basch’s clinical focus is prostate cancer.  

Publications by Ethan Basch

Basch E, Aronson N, Berg A, Flum D, Gabriel S, Goodman SN, Helfand M, Ioannidis JP, Lauer M, Meltzer D, Mittman B, Newhouse R, Normand SL, Schneeweiss S, Slutsky J, Tinetti M, Yancy C (Methodology Committee of the Patient-Centered Outcomes Research Institute [PCORI]). Methodological Standards and Patient-Centeredness in Comparative Effectiveness Research: the PCORI Perspective. JAMA 2012;307(15):1636-40. [PubMed Abstract] 

Basch E, Oliver TK, Vickers A, Thompson I, Kantoff P, Howard Parnes, Loblaw A, Roth B, Williams J, Nam RK. Screening for Prostate Cancer with Prostate-Specific Antigen (PSA) Testing: American Society of Clinical Oncology Recommendations. J Clin Oncol 2012;30(24):3020-3025. [PubMed Abstract]

Basch E. Beyond the FDA PRO Guidance: Steps toward integrating meaningful patient-reported outcomes into regulatory trials and US drug labels. Value Health 2012;15:401 403. [PubMed Abstract]

Basch E, Abernethy AP, Mullins CD, Reeve BB, Smith ML, Coons SJ, Sloan J, Wenzel K, Chauhan C, Eppard W, Frank ES, Lipscomb J, Raymond SA, Spencer M, Tunis S. Recommendations for Incorporating Patient-Reported Outcomes Into Clinical Comparative-Effectiveness Research in Adult Oncology. J Clin Oncol 2012; Oct 15 [Epub ahead of print]. [PubMed Abstract]

Basch E. The missing voice of patients in drug-safety reporting. N Engl J Med 2010;362(10):865-9. [PubMed Abstract]